Key result
Exosomes derived from Angiotensin II-induced cardiomyocytes inhibited cardiac microvascular endothelial cell proliferation, migration, and angiogenesis by transferring miR-29a to target VEGFA.
Why the study?
Whether cardiomyocyte-derived exosomal miR-29a regulates cardiac microvascular endothelial cell homeostasis during myocardial hypertrophy has not been determined.
Exosomes from Ang II-induced cardiomyocytes transfer miR-29a to cardiac microvascular endothelial cells, inhibiting their proliferation, migration, and angiogenesis by targeting VEGFA.
May impair CMEC angiogenesis in hypertrophy models; leaves open exosomal miR-29a targeting for clinical translation.
BACKGROUND: Exosomes released from cardiomyocytes (CMs) potentially play an important role in angiogenesis through microRNA (miR) delivery. Studies have reported an important role for miR-29a in regulating angiogenesis and pathological myocardial hypertrophy. However, whether CMderived exosomal miR-29a is involved in regulating cardiac microvascular endothelial cell (CMEC) homeostasis during myocardial hypertrophy has not been determined. METHODS: Angiotensin II (Ang II) was used to induce CM hypertrophy, and ultracentrifugation was then used to extract exosomes from a CM-conditioned medium. CMECs were cocultured with a conditioned medium in the presence or absence of exosomes derived from CMs (Nor-exos) or exosomes derived from angiotensin II-induced CMs (Ang II-exos). Moreover, a rescue experiment was performed using CMs or CMECs infected with miR-29a mimics or inhibitors. Tube formation assays, Transwell assays, and 5-ethynyl-20-deoxyuridine (EdU) assays were then performed to determine the changes in CMECs treated with exosomes. The miR-29a expression was measured by qRT-PCR, and Western blotting and flow cytometry assays were performed to evaluate the proliferation of CMECs. RESULTS: The results showed that Ang II-induced exosomal miR-29a inhibited the angiogenic ability, migratory function, and proliferation of CMECs. Subsequently, the downstream target gene of miR- 29a, namely, vascular endothelial growth factor (VEGFA), was detected by qRT-PCR and Western blotting, and the results verified that miR-29a targeted the inhibition of the VEGFA expression to subsequently inhibit the angiogenic ability of CMECs. CONCLUSION: Our results suggest that exosomes derived from Ang II-induced CMs are involved in regulating CMCE proliferation, migration, and angiogenesis by targeting VEGFA through the transfer of miR-29a to CMECs.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied Myocardial hypertrophy (in vitro model). Exosomes derived from Angiotensin II-induced cardiomyocytes (Ang II-exos) vs. Exosomes derived from normal cardiomyocytes (Nor-exos) was evaluated on Angiogenic ability, migratory function, and proliferation of CMECs. Exosomes derived from Angiotensin II-induced cardiomyocytes inhibited cardiac microvascular endothelial cell proliferation, migration, and angiogenesis by transferring miR-29a to target VEGFA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: